Jackson Acquisition Company (JACS) is a Special Purpose Acquisition Company (SPAC) — a blank check company with no operations, revenue, or employees. Its sole purpose is to acquire a private company and take it public through a merger, rather than a traditional IPO. JACS raised $230M in its IPO in December 2024, with proceeds held in a Trust Account earning interest until a deal closes or the company liquidates. JACS is focused primarily on healthcare services and healthcare technology, though management reserves the right to pursue targets outside healthcare. The sponsor is affiliated with Jackson Healthcare and Jackson Investment Group, both based in Alpharetta, Georgia. The sponsor purchased founder shares at a nominal price and bought Private Placement Units at $10.00/unit; if a deal closes, those founder shares — representing roughly 20% of post-IPO shares — become valuable, creating significant upside for the sponsor at relatively low cost. Public shareholders can redeem their shares for approximately $10.10/share at deal close or if no deal is completed by December 11, 2026, at which point JACS liquidates and returns Trust Account proceeds to public shareholders. The core value driver is whether management can identify and close a deal with a healthcare business before the December 2026 deadline.